In recent years, cancer research has entered an exciting new era in which a number of highly effective, non-toxic targeted cancer therapies have been developed based on improved understanding of the molecular underpinnings of cancer. Fundamental knowledge about the biology of cancer has burgeoned, but the translation of basic science discoveries to clinical advancements is slow and inefficient. The translation of molecular insights into clinical trials requires that teams of physician and scientists with diverse training work together. The objective of the Translational Research in Oncology Training (TROT) Program is to give Trainees at Memorial Sloan-Kettering Cancer Center (MSKCC) a solid foundation in the field of oncology research, while exposing them to the clinical care enterprise, so that they may make a vibrant link between clinical and basic research. The ultimate goal of the Program is to support the development of PhD scientists who possess the complex knowledge of their basic science discipline, but who additionally possess the ability to translate their research into clinically meaningful application. This Program will provide Trainees with the intensive training, resources, and experience necessary for them to develop successful careers in academia, government, and industry as independent translational researchers and leaders. The objective will be achieved by providing a structured learning environment where the Trainee will conduct a project under the mentorship of a successful, independent translational researcher. Didactic sessions, seminar series, and a retreat will reinforce their scientific training. Trainees will have the opportunity to observe patient interactions and procedures, and will learn about cancer diagnoses and staging through a rotation in Pathology. Each trainee will select a clinical mentor who will provide guidance, from a clinical perspective, on the Trainee's research project.
The training program for translational cancer research will provide opportunities to postdoctoral PhD trainees to learn about human oncology and pathogenesis, and work collaboratively with clinicians to advance the treatment of cancer patients. The goals are: to help basic scientists to develop a strong clinical background so that they may effectively bring discoveries from bench to bedside;and to foster interdisciplinary research and collaboration.
|Clark, Owen; Yen, Katharine; Mellinghoff, Ingo K (2016) Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clin Cancer Res 22:1837-42|
|Landa, IÃ±igo; Ibrahimpasic, Tihana; Boucai, Laura et al. (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052-66|
|David, Charles J; Huang, Yun-Han; Chen, Mo et al. (2016) TGF-Î² Tumor Suppression through a Lethal EMT. Cell 164:1015-30|
|Hakimi, A Ari; Reznik, Ed; Lee, Chung-Han et al. (2016) An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell 29:104-16|
|Brooks, Samira A; Khandani, Amir H; Fielding, Julia R et al. (2016) Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. Clin Cancer Res 22:2950-9|
|Pulitzer, Melissa P; Brannon, A Rose; Berger, Michael F et al. (2015) Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma. Mod Pathol 28:1023-32|
|Tan, Marcus C; Basturk, Olca; Brannon, A Rose et al. (2015) GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. J Am Coll Surg 220:845-54.e1|
|Watson, Philip A; Arora, Vivek K; Sawyers, Charles L (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15:701-11|
|Perry, Elizabeth B; Barrick, Jeffrey E; Bohannan, Brendan J M (2015) The Molecular and Genetic Basis of Repeatable Coevolution between Escherichia coli and Bacteriophage T3 in a Laboratory Microcosm. PLoS One 10:e0130639|
|Walsh, L A; Roy, D M; Reyngold, M et al. (2015) RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch. Oncogene 34:2189-203|
Showing the most recent 10 out of 31 publications